Telavancin (Theravance).
作者信息
Pace John L, Judice J Kevin
机构信息
LifeNet Inc, R&D Department, Virginia Beach, VA 23455, USA.
出版信息
Curr Opin Investig Drugs. 2005 Feb;6(2):216-25.
PMID:15751746
Abstract
Theravance is developing telavancin, an injectable peptidoglycan inhibitor antibiotic for potential use in the treatment of Gram-positive bacterial infection. Phase III trials in complicated skin and skin structure infections commenced in September 2004.
摘要
Zotero 插件